Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
Become a Member | Sign in
Home>News>This Article

Phytronix and Agilent to Co-Market Phytronix LDTD Ion Source with Agilent Mass Spectrometers

Published: Wednesday, June 10, 2009
Last Updated: Wednesday, June 10, 2009
Bookmark and Share
The non-exclusive co-marketing agreement aims to promote the Phytronix Laser Diode Thermal Desorption Ion Source with Agilent mass spectrometers.

Phytronix Technologies Inc. and Agilent Technologies Inc. announced they have signed a non-exclusive co-marketing agreement to promote the Phytronix Laser Diode Thermal Desorption (LDTD) Ion Source with Agilent mass spectrometers.

The LDTD Ion Source, used with an Agilent MS/MS can offer ultra fast sample analysis for both quantitative and qualitative applications in high-throughput environments such as drug discovery processes (ADMET and DMPK), toxicology, forensics, food safety, and environmental applications.

The LDTD complements Agilent’s 1200 Series HPLC-Chip/MS. The latter provides on-line LC/MS at nanoflow rates that are well-suited to applications where sample amount is limited. The LDTD is based on a shotgun approach, which uses the separation power of the mass spectrometer for high throughput small molecule quantization in a myriad of applications.

Agilent and Phytronix have co-developed the interface between the LDTD and Agilent mass spectrometers to provide life science users with throughput that can exceed 20,000 samples per week.

Under the agreement, the companies will co-market the LDTD and Agilent mass spectrometer systems with each company responsible for its individual products. Agilent will sell and support its mass spectrometers and Phytronix will sell and support the LDTD and the interface between the LDTD and Agilent mass spectrometers. Each company will co-promote their products at industry tradeshows and conferences.

“The combination of the LDTD with Agilent mass spectrometers provides a powerful tool for life science researchers,” said Jean Lacoursiere, Phytronix’s President.

“In particular the LDTD combined with the new Agilent 6530 Accurate-Mass Q-TOF and 6460 Triple Quadrupole instruments provides researchers with exceptional sensitivity and analytical speed. This LDTD-Agilent mass spectrometer system allows, for example, pharmacokinetic studies in less than 10 minutes as well as enzyme inhibition trials in 18 minutes rather than the 10 hours presently required with current methods of analysis.”

Ken Miller, Global Sr. Marketing Manager for Mass Spectrometry at Agilent, added, “The Phytronix LDTD system will be very complementary to the Agilent nanoflow HPLC-Chip technology. The LDTD ion source offers some added capabilities such as a run-time of 4 seconds per sample for high throughput analysis. Many of our customers have asked for the integration of the Phytronix system with our 6000 Series LC/MS products, especially the Agilent 6400 Series Triple Quadrupole LC/MS/MS system.”

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent Supports Inaugural Singapore-South Korea Symposium on Glycomics
Event follows collaboration to develop tools for analysis of biologics, vaccines.
Saturday, February 15, 2014
Agilent, Cell Line Genetics Collaborate
Companies to collaborate on high-throughput cell-line characterization services for regenerative medicine, cancer researchers.
Thursday, February 13, 2014
Agilent Joins Forces with Baylor College of Medicine
Collaboration will see Agilent and Baylor provide customized CGH microarrays for cancer, prenatal and postnatal research.
Thursday, November 14, 2013
Agilent and Seoul National University Hospital Collaborate
The strategic collaboration will focus on the development and verification of various biomarkers for the development of drugs, including narcotics, immune-suppressants and biomarkers.
Friday, October 18, 2013
Agilent Technologies to Separate into Two Public Companies
Life sciences, diagnostics and applied markets (LDA) that will retain the Agilent name, and the other company will be comprised of Agilent's electronic measurement (EM) products.
Monday, September 23, 2013
Agilent Technologies and SomaLogic Enter Agreement
The agreement will expand access to SomaLogic's unbiased protein biomarker discovery platform.
Tuesday, August 13, 2013
Agilent Technologies Announces Winner of Fifth Annual Early Career Professor Award
Assistant Professor at Northwestern Recognized for Cancer Diagnostics Research.
Friday, May 10, 2013
Agilent Technologies and Chungnam National University Announce Glycomics Research Initiatives
The collaboration hopes to develop biomarkers and new therapeutic antibodies to combat diseases such as cancer.
Tuesday, April 02, 2013
Agilent and Applied Proteomics Will Collaborate
Collaboration to maximize capabilities of highly multiplexed protein assays.
Friday, March 08, 2013
Agilent Technologies Collaborates with Gachon University
World-leading research laboratory at Gachon will have access to the latest technologies from Agilent and a beta test site for new solutions.
Monday, July 23, 2012
Agilent Technologies and Chungnam National University Collaborate to Further Glycomics Research
The university aims to identify and develop biomarkers for diseases.
Friday, August 26, 2011
Agilent Technologies Enters Second Phase of Collaboration to Map Human Proteome
Agilent’s collaboration with ISB and ETH Zurich for the mapping of the complete human proteome by mass spectrometry is enters its second phase.
Thursday, September 23, 2010
Agilent Updates Human Exon Target Enrichment Tool, Featuring Expressed Genome Content and Optimized Uniformity
The Latest SureSelect product to emerge from close collaboration with The Broad Institute.
Wednesday, August 25, 2010
Agilent and Los Alamos Develop First High-Throughput System to be Deployed at UCLA’s Global Bio Lab
Researchers are developing new tools for characterizing biological pathogens that could give rise to potentially deadly pandemics.
Thursday, June 11, 2009
Agilent Technologies, University of Michigan Partner on Research to Attack Prostate Cancer Using Systems Biology
Agilent Technologies announced its support of prostate cancer research by the University of Michigan’s Centre for Translational Pathology (MCTP) through a grant of instruments and funding.
Monday, March 23, 2009
Scientific News
NIH Supports New Studies to Find Alzheimer’s Biomarkers in Down Syndrome
Initiative will track dementia onset, progress in Down syndrome volunteers.
Genetic Basis of Fatal Flu Side Effect Discovered
A group of people with fatal H1N1 flu died after their viral infections triggered a deadly hyperinflammatory disorder in susceptible individuals with gene mutations linked to the overactive immune response, according to a recent study.
New Class of RNA Tumor Suppressors Identified
Two short, “housekeeping” RNA molecules block cancer growth by binding to an important cancer-associated protein called KRAS. More than a quarter of all human cancers are missing these RNAs.
Mathematical Model Forecasts the Path of Breast Cancer
Chances of survival depend on which organs breast cancer tumors colonize first.
Ancient Viral Molecules Essential for Human Development
Genetic material from ancient viral infections is critical to human development, according to researchers at the Stanford University School of Medicine.
Measuring microRNAs in Blood to Speed Cancer Detection
A simple, ultrasensitive microRNA sensor holds promise for the design of new diagnostic strategies and, potentially, for the prognosis and treatment of pancreatic and other cancers.
Personalized Drug Screening for Multiple Myeloma Patients
A personalized method for testing the effectiveness of drugs that treat multiple myeloma may predict quickly and more accurately the best treatments for individual patients with the bone marrow cancer.
Metabolic Profiles Distinguish Early Stage Ovarian Cancer with Unprecedented Accuracy
Studying blood serum compounds of different molecular weights has led scientists to a set of biomarkers that may enable development of a highly accurate screening test for early-stage ovarian cancer.
New Way to Force Stem Cells to Become Bone Cells
Potential therapies based on this discovery could help people heal bone injuries or set hardware, such as replacement knees and hips.
Promise of Newborn Stem Cells to Revolutionize Clinical Practice
In this article Shweta Sharma, PhD, discusses the potential of an Umbilical Cord Blood bank as an untapped source of samples for research and clinical trials.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos